Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Poor Prognosis AML or MDS
NCT00071006Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2003
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Objective Response (OR) up to 35 weeks. Started Sep 2003; status: completed.
02
Drugs
axitinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00071006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071006.